Gene therapy: a 2001 perspective

被引：16

作者：

High, KA ^{[1
]}

机构：

[1] Childrens Hosp Philadelphia, Dept Paediat, Philadelphia, PA 19104 USA

来源：

HAEMOPHILIA | 2001年 / 7卷

关键词：

haemophilia A; haemophilia B; gene therapy; retrovirus; AAV; plasmid;

D O I：

10.1046/j.1365-2516.2001.00098.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the past year, three clinical trials of gene therapy for haemophilia have been initiated. Years of preclinical studies have culminated in translation of research findings into the clinical arena. It is too early to predict which, if any, of these strategies will show efficacy. This paper will review basic aspects of gene therapy for haemophilia and will briefly outline current clinical trials. The three clinical trials all share a dose escalation design. The ongoing trial for haemophilia B involves the intramuscular administration of an adenoassociated virus (AAV) vector expressing human factor IX. In preclinical studies, this strategy has produced therapeutic levels of circulating factor IX in haemophilic mice and dogs.

引用

页码：23 / 27

页数：5

共 25 条

[1] TARGETED DISRUPTION OF THE MOUSE FACTOR-VIII GENE PRODUCES A MODEL OF HEMOPHILIA-A [J].

BI, L ;

LAWLER, AM ;

ANTONARAKIS, SE ;

HIGH, KA ;

GEARHART, JD ;

KAZAZIAN, HH .

NATURE GENETICS, 1995, 10 (01) :119-121

[2]

BRETTLER DB, 1990, BLOOD, V76, P254

[3] The canine factor VIII cDNA and 5′ flanking sequence [J].

Cameron, C ;

Notley, C ;

Hoyle, S ;

McGlynn, L ;

Hough, C ;

Kamisue, S ;

Giles, A ;

Lillicrap, D .

THROMBOSIS AND HAEMOSTASIS, 1998, 79 (02) :317-322

[4] CANINE HEMOPHILIA-B RESULTING FROM A POINT MUTATION WITH UNUSUAL CONSEQUENCES [J].

EVANS, JP ;

BRINKHOUS, KM ;

BRAYER, GD ;

REISNER, HM ;

HIGH, KA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (24) :10095-10099

[5] Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX [J].

Fields, PA ;

Kowalczyk, DW ;

Arruda, VR ;

Armstrong, E ;

McCleland, ML ;

Hagstrom, JN ;

Pasi, KJ ;

Ertl, HCJ ;

Herzog, RW ;

High, KA .

MOLECULAR THERAPY, 2000, 1 (03) :225-235

[6] HEPATITIS-B VIRUS, HEPATITIS-A VIRUS AND PERSISTENTLY ELEVATED AMINOTRANSFERASES IN HEMOPHILIACS [J].

GERETY, RJ ;

EYSTER, ME ;

TABOR, E ;

DRUCKER, JA ;

LUSCH, CJ ;

PRAGER, D ;

RICE, SA ;

BOWMAN, HS .

JOURNAL OF MEDICAL VIROLOGY, 1980, 6 (02) :111-118

[7] Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector [J].

Herzog, RW ;

Yang, EY ;

Couto, LB ;

Hagstrom, JN ;

Elwell, D ;

Fields, PA ;

Burton, M ;

Bellinger, DA ;

Read, MS ;

Brinkhous, KM ;

Podsakoff, GM ;

Nichols, TC ;

Kurtzman, GJ ;

High, KA .

NATURE MEDICINE, 1999, 5 (01) :56-63

[8] Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus [J].

Herzog, RW ;

Hagstrom, JN ;

Kung, SH ;

Tai, SJ ;

Wilson, JM ;

Fisher, KJ ;

High, KA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (11) :5804-5809

[9] Gene therapy for the hemophilias [J].

Kay, MA ;

High, K .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (18) :9973-9975

[10] IN-VIVO GENE-THERAPY OF HEMOPHILIA-B - SUSTAINED PARTIAL CORRECTION IN FACTOR-IX-DEFICIENT DOGS [J].

KAY, MA ;

ROTHENBERG, S ;

LANDEN, CN ;

BELLINGER, DA ;

LELAND, F ;

TOMAN, C ;

FINEGOLD, M ;

THOMPSON, AR ;

READ, MS ;

BRINKHOUS, KM ;

WOO, SLC .

SCIENCE, 1993, 262 (5130) :117-119

← 1 2 3 →